Cancer vaccines: Will we ever learn?

Expert Review of Anticancer Therapy

Volumn 9, Issue 1, 2009, Pages 67-74

  Johnson, Robert S ^a   Walker, Anthony I ^a   Ward, Stephen J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant; Antigen; Cancer vaccine; Cell based; Immunotherapy; Minimal residual disease

Indexed keywords

BIOVAXID; CANCER VACCINE; CANVAXIN; CDX 110; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GV 1001; INTERLEUKIN 10; IPILIMUMAB; MEGAVAX; MELANOMA ANTIGEN 3 VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MYVAX; ONY P; ONYVAX; PANVAC VF; PLACEBO; PROVENGE; RENIALE; SPECIFID; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITESPEN;

ADJUVANT THERAPY; ARTICLE; B CELL LYMPHOMA; BRAIN SURGERY; CANCER IMMUNIZATION; CANCER RELAPSE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; COLORECTAL TUMOR; IMMUNOLOGY; KIDNEY TUMOR; MALE; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR;

CANCER VACCINES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MELANOMA; PROSTATIC NEOPLASMS;

EID: 61449280353     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.1.67     Document Type: Article

References (30)

1. Smith TJ, Desch CE, David M, Somerfield MR. Would oncologists want chemotherapy if they had non-small-cell lung cancer? Oncology (Williston Park) 12(3), 360, 363, 365 (1998).
2. Burnet FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970)
3. Coley WB. Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199-200 (1891).
4. Lowy I. Experimental systems and clinical practices: tumor immunology and cancer immunotherapy, 1895-1980. J. Hist. Biol. 27(3), 403-435 (1994).
5. Bower M, Mazhar D and Stebbing J. What's the (end) point of cancer vaccines. Expert Rev. Anticancer Ther. 6(8), 1133-1149 (2006).
6. Eaton JD, Perry MJA, Nicholson S et al. Allogeneic whole-cell vaccine: a Phase I/II study in men with hormone-refractory prostate cancer. BJU Int. 89, 19-26 (2002).
7. Hanna MG Jr, Hoover HC Jr, Pinedo HM, Finer M. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological pharmacodynamics. Hum. Vaccin. 2(4), 185-191 (2006)
8. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353(9150), 345-350 (1999).
9. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumor cell vaccine and risk of tumor progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomized controlled trial. Lancet 363(9409), 594-599 (2004)
10. Doehn C, Richter A, Theodor RA et al. Prolongaion of progression-free and overall survival following adjuvant vaccination with Reniale in patients with non-metastatic renal carcinoma. Presented at: Program and Abstracts of the 27th German Cancer Congress. Berlin, Germany, 22-26 March 2006 (Abstract 395).
11. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5(10), 1171-1177 (1999).
12. Neelapu SS, Gause BL, Nikcevich DA et al. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report Clin. Lymphoma 6(1), 61-64 (2005).
13. Wierecky J, Mueller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006).
14. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Onc. (Meeting Abstracts) 25(18 Suppl.), 7554 (2007).
15. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 9, 4247-4254 (2003).
16. Sampson JH, Archer GE, Bigner DD et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 2011).
17. Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11(12), 4469-4478 (2005).
18. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol. Ther. 24(8), 1163-1177 (2006).
19. Madan RA, Gulley JL, Schlom J et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy Clin. Cancer Res. 14(14), 4526-4531 (2008).
20. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64(24), 9209-9216 (2004)
21. Gerritsen WR, van den Eertwegh AJ, de Gruijl TD et al. Expanded Phase 1 combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5146).
22. Chiarella P, Vulcano M, Bruzzo J et al. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol. Immunother. 57(5), 701-718 (2008).
23. Copier J, Ward S, Dalgleish AG. Cell based cancer vaccines: regulatory and commercial develoment Vaccine 25(Suppl.), B35-B46 (2007).
24. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline Annex to Q8: Pharmaceutical Development (2007).
25. Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology 31(3-4), 177-202 (1975).
26. Dalgleish AG. Cancer vaccines as a therapeutic strategy. Expert Rev. Vaccines 3(6), 665-668 (2004)
27. Morton DL. An international, randomized, Phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
28. Mulders P, Wood CG, Gorelov S et al. A multicentre, randomized, Phase III trial of a novel, autologous, therapeutic vaccine (vitespen) vs observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma Presented at: 23rd Annual European Association of Urology Congress. Milan, Italy, 26-29 March 2008.
29. Kafi K, Betting D, Yamada R, Steward K, Timmerman JM, Effect on in vivo immunogenicity of human idiotype-KLH vaccines by maleimide conjugation. J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 8576).
30. Levy R, Robertson MJ, Ganjoo K et al. Results of a Phase III trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL). Presented at: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. San Diego, CA, USA, 12-16 April 2008 (Abstract LB204).